The drugs currently used for the treatment of NAFLD, such as insulin sensitizer pioglitazone, farnesoid X receptor agonist obeticholic acid, and the thyroid hormone receptor THRβ agonist Resmetirom, target various pathways. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.